Amgen (AMGN) Tuesday said that, in a clinical trial, evolocumab was found to have the potential to treat hyperlipidemia for patients who cannot control their cholesterol levels.
Evolocumab is said to inhibit a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol, also known as bad cholesterol, from the blood.
"Many patients with high cholesterol struggle to adequately reduce their LDL-C, a significant contributor to cardiovascular disease," said Michael Koren, M.D., of the Jacksonville Center for Clinical Research.
The 52-week open label study, showed that monthly treatment Evolocumab reduced cholesterol levels up to 52 percent in combination with SOC in patients with high cholesterol, and also prevented major increase in adverse events.
Meanwhile, 81.4 percent of patients showed adverse events including nasopharyngitis, upper respiratory tract infections, influenza, arthralgia, and back pain. Other minor reported events include muscle-problems, elevated liver function, elevated creatine kinase.
An open-label extension study evaluating the long-term safety and efficacy of evolocumab in patients with high cholesterol, is currently ongoing.
According to the Centers for Disease Control and Prevention, more than 71 million American adults have high LDL-C.2 Elevated LDL-C is recognized as a major risk factor for cardiovascular disease.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.